Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
SYRUP
**RECOMMENDED DOSAGE:** Orally Adults :10 – 20 ml (5ml for elderly and sensitive patients)Children :2 – 5 yrs : 2.5 – 5ml6 – 12 yrs : 5mlOver 12 years: 5–10 ml Doses to be given 3 – 4 times daily. _Special patient groups:_ In elderly patients or in those known to be unusually sensitive to beta-adrenergic stimulant drugs, it is advisable to initiate treatment with 2 mg (5ml) salbutamol 3 or 4 times per day.
ORAL
Medical Information
**INDICATIONS:** For the relief and prevention of bronchospasm in bronchial asthma, in chronic bronchitis, and in emphysema. Bronchodilators should not be the only or main treatment in patients with persistent asthma. In patients with persistent asthma unresponsive to ZENMOLIN, treatment with inhaled corticosteroids is recommended to achieve and maintain control. Failing to respond to treatment with ZENMOLIN may signal a need for urgent medical advice or treatment.
**Contraindications** Salbutamol syrup is contraindicated in patients with a history of hypersensitivity to any of its components. Non-i.v. formulations of Salbutamol must not be used to arrest uncomplicated premature labour or threatened abortion.
R03CC02
salbutamol
Manufacturer Information
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
PT ACTAVIS INDONESIA
Active Ingredients
Documents
Package Inserts
Zenmolin Syrup PI.pdf
Approved: December 30, 2022